Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1492298,
author = {Gregorová, Michaela and Janovská, Pavlína and Němec, Václav and Scholasterová, Michaela and Verner, Jan and Poppová, Lucie and Pavlová, Šárka and Plevová, Karla and Pospíšilová, Šárka and Paruch, Kamil and Bryja, Vítězslav},
booktitle = {HemaSpehere},
keywords = {Therapy - Wnt - Inhibitor},
language = {eng},
title = {Development of selective casein kinase 1 delta/epsilon inhibitors for cancer},
year = {2018}
}
TY - CONF
ID - 1492298
AU - Gregorová, Michaela - Janovská, Pavlína - Němec, Václav - Scholasterová, Michaela - Verner, Jan - Poppová, Lucie - Pavlová, Šárka - Plevová, Karla - Pospíšilová, Šárka - Paruch, Kamil - Bryja, Vítězslav
PY - 2018
TI - Development of selective casein kinase 1 delta/epsilon inhibitors for cancer
KW - Therapy - Wnt - Inhibitor
N2 - Casein kinase 1 (CK1) is a key component of both canonical and non-canonical Wnt pathways, which were shown to drive chronic lymphocytic leukemia (CLL) by several mechanisms (Wang et al., 2014, Kaucka et al., 2013). Also other types of cancer, such as breast, prostate cancer or others were previously shown to depend on Wnt/CK1 activity and the pathway inhibition was suggested as a potential form of therapy. In recent study, we showed that CK1 inhibition can block processes involved in CLL progression in vitro as well as in vivo in the Eµ-TCL1 mouse model of CLL (Janovska et al., 2018). Importantly, CK1 inhibition showed synergistic effects with ibrutinib treatment in blocking chemotaxis of CLL cells, a process important for CLL pathogenesis and showed to be beneficial also in vivo.
ER -
GREGOROVÁ, Michaela, Pavlína JANOVSKÁ, Václav NĚMEC, Michaela SCHOLASTEROVÁ, Jan VERNER, Lucie POPPOVÁ, Šárka PAVLOVÁ, Karla PLEVOVÁ, Šárka POSPÍŠILOVÁ, Kamil PARUCH a Vítězslav BRYJA. Development of selective casein kinase 1 delta/epsilon inhibitors for cancer. In \textit{HemaSpehere}. 2018. ISSN~2572-9241.
|
